152 related articles for article (PubMed ID: 8467488)
1. Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells.
Evans CA; Owen-Lynch PJ; Whetton AD; Dive C
Cancer Res; 1993 Apr; 53(8):1735-8. PubMed ID: 8467488
[TBL] [Abstract][Full Text] [Related]
2. Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line.
Carlesso N; Griffin JD; Druker BJ
Oncogene; 1994 Jan; 9(1):149-56. PubMed ID: 8302574
[TBL] [Abstract][Full Text] [Related]
3. The suppression of drug-induced apoptosis by activation of v-ABL protein tyrosine kinase.
Chapman RS; Whetton AD; Dive C
Cancer Res; 1994 Oct; 54(19):5131-7. PubMed ID: 7923130
[TBL] [Abstract][Full Text] [Related]
4. v-Abl protein tyrosine kinase (PTK) mediated suppression of apoptosis is associated with the up-regulation of Bcl-XL.
Chen Q; Turner J; Watson AJ; Dive C
Oncogene; 1997 Oct; 15(18):2249-54. PubMed ID: 9393984
[TBL] [Abstract][Full Text] [Related]
5. Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation.
Pierce A; Spooncer E; Wooley S; Dive C; Francis JM; Miyan J; Owen-Lynch PJ; Dexter TM; Whetton AD
Oncogene; 2000 Nov; 19(48):5487-97. PubMed ID: 11114726
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Abelson oncogene function by erbstatin analogues.
Kawada M; Tawara J; Tsuji T; Honma Y; Hozumi M; Wang JY; Umezawa K
Drugs Exp Clin Res; 1993; 19(6):235-41. PubMed ID: 8013266
[TBL] [Abstract][Full Text] [Related]
9. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.
Chai SK; Nichols GL; Rothman P
J Immunol; 1997 Nov; 159(10):4720-8. PubMed ID: 9366395
[TBL] [Abstract][Full Text] [Related]
10. bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia.
Hariharan IK; Adams JM; Cory S
Oncogene Res; 1988; 3(4):387-99. PubMed ID: 3147434
[TBL] [Abstract][Full Text] [Related]
11. Drosophila abelson interacting protein (dAbi) is a positive regulator of abelson tyrosine kinase activity.
Juang JL; Hoffmann FM
Oncogene; 1999 Sep; 18(37):5138-47. PubMed ID: 10498863
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
[TBL] [Abstract][Full Text] [Related]
13. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
Danhauser-Riedl S; Warmuth M; Druker BJ; Emmerich B; Hallek M
Cancer Res; 1996 Aug; 56(15):3589-96. PubMed ID: 8758931
[TBL] [Abstract][Full Text] [Related]
14. Characterization of drug resistance mediated via the suppression of apoptosis by Abelson protein tyrosine kinase.
Chapman RS; Whetton AD; Chresta CM; Dive C
Mol Pharmacol; 1995 Aug; 48(2):334-43. PubMed ID: 7651367
[TBL] [Abstract][Full Text] [Related]
15. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study).
Zhelev Z; Bakalova R; Ohba H; Ewis A; Ishikawa M; Shinohara Y; Baba Y
FEBS Lett; 2004 Jul; 570(1-3):195-204. PubMed ID: 15251464
[TBL] [Abstract][Full Text] [Related]
16. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148.
Dan S; Naito M; Tsuruo T
Cell Death Differ; 1998 Aug; 5(8):710-5. PubMed ID: 10200527
[TBL] [Abstract][Full Text] [Related]
17. p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
Brusa G; Benvenuti M; Mazzacurati L; Mancini M; Pattacini L; Martinelli G; Barbieri E; Greenberger JS; Baccarani M; Santucci MA
Haematologica; 2003 Jun; 88(6):622-30. PubMed ID: 12801837
[TBL] [Abstract][Full Text] [Related]
18. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.
Forster K; Obermeier A; Mitina O; Simon N; Warmuth M; Krause G; Hallek M
Ann Hematol; 2008 Mar; 87(3):183-93. PubMed ID: 17960378
[TBL] [Abstract][Full Text] [Related]
19. Role of the C-terminal actin binding domain in BCR/ABL-mediated survival and drug resistance.
Underhill-Day N; Pierce A; Thompson SE; Xenaki D; Whetton AD; Owen-Lynch PJ
Br J Haematol; 2006 Mar; 132(6):774-83. PubMed ID: 16487179
[TBL] [Abstract][Full Text] [Related]
20. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
